

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A controlled release pharmaceutical formulation, comprising: an effective amount of L-threo-DOPS, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an extended release form.
2. (Original) A controlled release pharmaceutical formulation of claim 1, wherein the extended release form is a dissolution controlled release delivery system.
3. (Original) A controlled release pharmaceutical formulation of claim 2, wherein the dissolution controlled release delivery system is oral and comprises a slowly soluble material which is selected from the group consisting of: ethylcellulose, cellulose acetate phthalate, acrylic resins, methacrylate hydrogels, methylmethacrylate, polymethacrylate, polylactic acid, polyvinyl chloride, polyvinyl chloride, polymethacrylate, hydroxypropylmethylcellulose, polyethylene glycols, carboxymethylcellulose, and sodium carboxymethylcellulose.
4. (Original) A controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is non-oral and maintains the release of L-threo-DOPS, a derivative thereof, or salt thereof, over a period of at least 24 hours.
5. (Original) The controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is oral and suitable for once-daily administration.
6. (Original) The controlled release pharmaceutical formulation of claim 1, wherein the controlled release formulation is oral and suitable for twice- or three-times daily administration.
7. (Original) A controlled release pharmaceutical formulation of claim 1, further comprising an effective amount of L-threo-DOPS, a derivative thereof, or a pharmaceutically-acceptable salt thereof, in an immediate release form.

8. (Original) A controlled release pharmaceutical formulation of claim 7, wherein the formulation comprises 45-85% by weight of total active drug of L-threo-DOPS in extended release form and 15-55% by weight of total active drug of L-threo-DOPS in immediate release form.
9. (Original) A controlled release pharmaceutical composition of claim 1 which is for oral use.
10. (Currently Amended) A controlled release pharmaceutical composition of claim 1, further comprising a pharmaceutically-acceptable carrier.